Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print


Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com


Direct vs. Video Laryngoscopy in 10 Minutes

Buscar en contenido


domingo, 20 de octubre de 2013


"The CRASH-3 trial is a large, international, randomised, placebo controlled trial, to quantify the safety and effect on mortality and morbidity of the administration of tranexamic acid in patients with TBI. Adults with TBI, who are within eight hours of injury, with any intracranial bleeding on CT scan or who have a GCS of 12 or less, and have no significant extra-cranial haemorrhage, are eligible for inclusion, except those for whom antifibrinolytic agents are thought to be clearly indicated or clearly contra-indicated. Treatment will be allocated randomly and numbered drug /placebo packs will be available in participating hospitals. The primary outcome will be death in hospital within 28 days of injury (cause of death will be described). Outcomes will be assessed at death, discharge or 28 days after randomisation, whichever occurs first."